Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021Business Wire • 08/02/21
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry GamechangersBusiness Wire • 07/01/21
Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant PatientsBenzinga • 06/07/21
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual ConnectBusiness Wire • 06/07/21
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation SummitBusiness Wire • 05/13/21
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific OfficerBusiness Wire • 05/10/21
Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational ProgressBusiness Wire • 05/04/21
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021Business Wire • 04/27/21
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual MeetingBusiness Wire • 03/14/21
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational ProgressBusiness Wire • 03/01/21
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021Business Wire • 02/18/21
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital ExperienceBusiness Wire • 02/08/21
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital ExperienceBusiness Wire • 01/19/21
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/10/21
Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS RatingInvestors Business Daily • 01/08/21
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative DiseaseBusiness Wire • 01/04/21
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual MeetingBusiness Wire • 12/07/20